We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
NewAmsterdam Pharma Company NV | NASDAQ:NAMSW | NASDAQ | Equity Warrant |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.11 | -1.16% | 9.39 | 0.0101 | 2,147.48 | 10.00 | 9.30 | 9.30 | 1,982 | 21:00:06 |
A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company’s website.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as preferred LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company ContactMatthew PhilippeP: 1-917-882-7512matthew.philippe@newamsterdampharma.com
Media ContactSpectrum Science on behalf of NewAmsterdamJen GordonP: 1-202-957-7795jgordon@spectrumscience.com
Investor ContactStern Investor Relations on behalf of NewAmsterdamHannah DeresiewiczP: 1-212-362-1200hannah.deresiewicz@sternir.com
1 Year NewAmsterdam Pharma Comp... Chart |
1 Month NewAmsterdam Pharma Comp... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions